Luvometinib in Combination With Serplulimab for NF2-Related Tumors | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Luvometinib in Combination With Serplulimab for NF2-Related Tumors	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ear Diseases, NF2-related schwannomatosis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Otorhinolaryngologic Neoplasms, acoustic neuroma, central nervous system cancer, cranial nerve neoplasm, cranial nerve neuropathy, hereditary disease, hereditary neoplastic syndrome, inherited neurodegenerative disorder, meningioma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurocutaneous syndrome, neurodegenerative disease, neuroendocrine neoplasm, neurofibroma, neurofibromatosis, neuroma, otorhinolaryngologic disease, peripheral nervous system neoplasm, primitive neuroectodermal tumor, retrocochlear disease, schwannoma, tumor of meninges, vascular cancer, vestibulocochlear nerve disorder	Not yet recruiting	Phase 1 / Phase 2	2026-07-16		NCT07708285

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Beijing Tiantan Hospital	307

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Tiantan Hospital, Capital Medical University	Beijing	China	59
Chinese PLA General Hospital	Beijing	China	87
Shanghai General Hospital	Shanghai	China	59
The First Hospital of Jilin University	Changchun	China	46
Xuanwu Hospital, Capital Medical University	Beijing	China	37